Document Detail


First report of drug-induced esophagitis by deferasirox.
MedLine Citation:
PMID:  22547195     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Deferasirox is a new oral iron chelator used to treat transfusional iron overload. We describe a case of a 79-year-old man with myelodysplastic syndrome (MDS) who developed esophagitis induced by deferasirox. He repeatedly received multiple red blood cell transfusions after a diagnosis of MDS. Two years after starting red blood cell transfusions, he was diagnosed with iron overload, and was then started on deferasirox at 1 g/day with about 400 ml of water. He was admitted to our institution because he was unable to swallow his own saliva 1 month after starting deferasirox. Esophagogastroendoscopy revealed white-coated mucosa covering the entire esophagus. A component analysis of biopsy specimens using high-performance liquid chromatography identified deferasirox. Symptoms resolved within about 2 weeks after discontinuing deferasirox, and repeated endoscopy showed marked improvement of esophagitis after 1 month. Re-administration of deferasirox was not attempted. Unfortunately, the patient died due to pneumonia 6 months after administration of deferasirox was started. This is the first report of drug-induced esophagitis associated with deferasirox.
Authors:
Takeshi Yoshikawa; Takeshi Hara; Hiroshi Araki; Hisashi Tsurumi; Masami Oyama; Hisataka Moriwaki
Related Documents :
1316075 - Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated u...
18193385 - An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropen...
1337525 - Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxaz...
7027925 - Treatment of uncomplicated urinary tract infections with trimethoprim versus sulfisoxaz...
9344575 - Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripher...
20922625 - Long-term outcomes following repair or replacement in degenerative mitral valve disease.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-05-01
Journal Detail:
Title:  International journal of hematology     Volume:  95     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-15     Completed Date:  2012-11-08     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  689-91     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Kisogawa Municipal Hospital, Aichi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Benzoates / adverse effects*,  therapeutic use
Blood Transfusion / adverse effects
Esophagitis / chemically induced*,  diagnosis,  pathology
Humans
Iron Chelating Agents / adverse effects*
Iron Overload / complications,  drug therapy
Male
Myelodysplastic Syndromes / complications,  therapy
Triazoles / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Benzoates; 0/Iron Chelating Agents; 0/Triazoles; V8G4MOF2V9/deferasirox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antihypertensive properties of Allium sativum (garlic) on normotensive and two kidney one clip hyper...
Next Document:  Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection i...